Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation

被引：7

作者：

Basak, G. W. ^{[1
]}

de Wreede, L. C. ^{[2
]}

van Biezen, A. ^{[2
]}

Wiktor-Jedrzejczak, W. ^{[1
]}

Halaburda, K. ^{[1
]}

Schmid, C. ^{[3
]}

Schaap, N. ^{[4
]}

Dazzi, F. ^{[5
]}

von dem Borne, P. A. ^{[6
]}

Petersen, E. ^{[7
]}

Beelen, D. ^{[8
]}

Abayomi, A. ^{[9
]}

Volin, L. ^{[10
]}

Buzyn, A. ^{[11
]}

Gurman, G. ^{[12
]}

Bunjes, D. ^{[13
]}

Guglielmi, C. ^{[14
]}

Olavarria, E. ^{[15
]}

de Witte, T. ^{[16
]}

机构：

[1] Med Univ Warsaw, Dept Hematol Oncol & Internal Dis, Warsaw, Poland

[2] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands

[3] Univ Munich, Klinikum Augsburg, Med Klin 2, Augsburg, Germany

[4] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands

[5] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England

[6] Leiden Univ, Med Ctr, Leiden, Netherlands

[7] Univ Med Ctr, Dept Hematol, Utrecht, Netherlands

[8] Univ Hosp, Dept Bone Marrow Transplantat, Essen, Germany

[9] Constantiaberg Medi Clin, Cape Hematol & Bone Marrow Transplant Unit, Cape Town, South Africa

[10] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland

[11] Hop Necker Enfants Malad, Serv Hematol Adulte, Paris, France

[12] Ankara Univ, Fac Med, Dept Hematol, TR-06100 Ankara, Turkey

[13] Univ Ulm Klinikum, Innere Med Klin 3, Ulm, Germany

[14] Univ Roma La Sapienza, Fac Med & Chirurg 2, Rome, Italy

[15] Hosp Navarra, Serv Hematol, Pamplona, Spain

[16] Radboud Univ Nijmegen Med Ctr, Dept Hematol, Nijmegen, Netherlands

来源：

BONE MARROW TRANSPLANTATION | 2013年 / 48卷 / 06期

基金：

英国医学研究理事会;

关键词：

DLI; alloSCT; CML; CHRONIC MYELOGENOUS LEUKEMIA; VERSUS-HOST-DISEASE; UNRELATED DONORS; MOBILIZED BLOOD; SURVIVAL; EFFICACY; EBMT; DLI;

D O I：

10.1038/bmt.2012.234

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We decided to retrospectively analyze the impact of stem cell source on the OS of CML patients who relapsed after either matched related donor PBSCT (N = 168) or BMT (N = 216) and were treated with donor lymphocyte infusions (DLI). Univariate analysis revealed a lower probability of OS after DLI in patients relapsing after PBSCT vs BMT (66% vs 79% at 5 years, P = 0.013). However, a multivariate Cox analysis did not reveal any significant impact of PBSCT as a risk factor for decreased OS for patients transplanted in first chronic phase (CP1; hazard ratio (HR) 1.036, 95% confidence interval (CI) 0.619-1.734). A statistical interaction term suggested that the impact of stem cell source on OS after DLI was different for those transplanted in advanced phases (negative impact of previous PBSCT-HR 2.176, 95% CI 0.930-5.091). In summary, the stem cell source does not affect the OS of CML patients who underwent PBSCT in CP1, relapsed and were treated with DLI. However, when the patients were transplanted in advanced phases, previous PBSCT seems to negatively affect OS after DLI compared with BMT.

引用

页码：837 / 842

页数：6

共 21 条

[1] Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials [J].

al-Jurf, M ;

Aranha, F ;

Annassetti, C ;

Apperley, JF ;

Baynes, R ;

Bensinger, WI ;

Blaise, D ;

Chaudhary, MA ;

Clarke, M ;

Cornelissen, JJ ;

Couban, S ;

Cutler, C ;

Djulbegovic, B ;

Gyger, M ;

Gratwohl, A ;

Heldal, D ;

Van der Holt, B ;

Hozo, I ;

Kuentz, M ;

Kumar, A ;

Lipton, J ;

Matchamm, J ;

Mohty, M ;

Morton, J ;

Panzarella, T ;

Powles, R ;

Richards, SM ;

Sahovic, E ;

Schmitz, N ;

Simpson, DR ;

Sirohi, B ;

Soares, HP ;

de Souza, CA ;

Vigorito, AC ;

Wheatley, K .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5074-5087

[2] Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant [J].

Alyea, EP ;

Soiffer, RJ ;

Canning, C ;

Neuberg, D ;

Schlossman, R ;

Pickett, C ;

Collins, H ;

Wang, YL ;

Anderson, KC ;

Ritz, J .

BLOOD, 1998, 91 (10) :3671-3680

[3] The EBMT activity survey 2009: trends over the past 5 years [J].

Baldomero, H. ;

Gratwohl, M. ;

Gratwohl, A. ;

Tichelli, A. ;

Niederwieser, D. ;

Madrigal, A. ;

Frauendorfer, K. .

BONE MARROW TRANSPLANTATION, 2011, 46 (04) :485-501

[4] The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse [J].

Carlens, S ;

Remberger, M ;

Aschan, J ;

Ringdén, O .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (01) :31-38

[5] Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT [J].

Chalandon, Y. ;

Passweg, J. R. ;

Schmid, C. ;

Olavarria, E. ;

Dazzi, F. ;

Simula, M. P. ;

Ljungman, P. ;

Schattenberg, A. ;

de Witte, T. ;

Lenhoff, S. ;

Jacobs, P. ;

Volin, L. ;

Iacobelli, S. ;

Finke, J. ;

Niederwieser, D. ;

Guglielmi, C. .

BONE MARROW TRANSPLANTATION, 2010, 45 (03) :558-564

[6] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].

Collins, RH ;

Shpilberg, O ;

Drobyski, WR ;

Porter, DL ;

Giralt, S ;

Champlin, R ;

Goodman, SA ;

Wolff, SN ;

Hu, W ;

Verfaillie, C ;

List, A ;

Dalton, W ;

Ognoskie, N ;

Chetrit, A ;

Antin, JH ;

Nemunaitis, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444

[7]

Dazzi F, 2000, Hematol J, V1, P307, DOI 10.1038/sj.thj.6200051

[8]

Dazzi F, 2000, BLOOD, V96, P2712

[9] Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival [J].

Eapen, Mary ;

Logan, Brent R. ;

Confer, Dennis L. ;

Haagenson, Michael ;

Wagner, John E. ;

Weisdorf, Daniel J. ;

Wingard, John R. ;

Rowley, Scott D. ;

Stroncek, David ;

Gee, Adrian P. ;

Horowitz, Mary M. ;

Anasetti, Claudio .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (12) :1461-1468

[10] Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia [J].

Elmaagacli, AH ;

Basoglu, S ;

Peceny, R ;

Trenschel, R ;

Ottinger, H ;

Lollert, A ;

Runde, V ;

Grosse-Wilde, H ;

Beelen, DW ;

Schaefer, UW .

BLOOD, 2002, 99 (04) :1130-1135

← 1 2 3 →